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Acute effects of ferumoxytol on 
regulation of renal hemodynamics 
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The superparamagnetic iron oxide nanoparticle ferumoxytol is increasingly used as intravascular 
contrast agent in magnetic resonance imaging (MRI). This study details the impact of ferumoxytol 
on regulation of renal hemodynamics and oxygenation. In 10 anesthetized rats, a single intravenous 
injection of isotonic saline (used as volume control) was followed by three consecutive injections of 
ferumoxytol to achieve cumulative doses of 6, 10, and 41 mg Fe/kg body mass. Arterial blood pressure, 
renal blood flow, renal cortical and medullary perfusion and oxygen tension were continuously 
measured. Regulation of renal hemodynamics and oxygenation was characterized by dedicated 
interventions: brief periods of suprarenal aortic occlusion, hypoxia, and hyperoxia. None of the three 
doses of ferumoxytol resulted in significant changes in any of the measured parameters as compared 
to saline. Ferumoxytol did not significantly alter regulation of renal hemodynamics and oxygenation 
as studied by aortic occlusion and hypoxia. The only significant effect of ferumoxytol at the highest 
dose was a blunting of the hyperoxia-induced increase in arterial pressure. Taken together, ferumoxytol 
has only marginal effects on the regulation of renal hemodynamics and oxygenation. This makes 
ferumoxytol a prime candidate as contrast agent for renal MRI including the assessment of renal blood 
volume fraction.
Ferumoxytol consists of iron oxide nanoparticles encapsulated by a polyglucose sorbitol carboxymethylether 
coating that is approved in the USA and the EU as intravascular iron supplementation therapy for patients with 
iron deficiency anemia related to chronic kidney disease (CKD). Since ferumoxytol is superparamagnetic, it is 
increasingly used off-label as contrast agent in magnetic resonance imaging (MRI) for a broad spectrum of pre-
clinical and diagnostic imaging applications1–9. Ferumoxytol has been proven very useful for vascular MRI since 
it can be administered by intravenous injection and exhibits a long intravascular half-life of >14 hours in humans 
and about 2 hours in small rodents1,2,7. Applications range from angiography of various vascular beds including 
the renal vasculature to the assessment of the blood volume fraction1–3,5–7. The latter is of relevance for blood 
oxygenation level-dependent (BOLD) MRI, because the effective relaxation time T2* is linked to the amount of 
deoxygenated hemoglobin per tissue volume (voxel). BOLD MRI is increasingly utilized for the study of kidney 
disorders10–14. Since the impact of the renal blood volume fraction and its changes obviously exceed that of other 
organs such as the brain, assessment of the renal blood volume fraction is a prerequisite for unambiguous inter-
pretation of renal BOLD MRI10,11.
The safety profile of ferumoxytol has mainly been assessed in anemic patients with CKD for whom ferumox-
ytol was originally approved3. A typical single dose in adult patients amounts to 510 mg Fe. The most serious 
adverse effect reported in the respective clinical trials was allergic responses; the FDA released warnings and 
changed prescribing instructions to decrease the risk of serious allergic reactions following intravenous iron 
replacement with ferumoxytol15. Hypotensive episodes were also observed in < 2% of adult patients1,3.
The dose for ferumoxytol as off-label MR contrast agent is widely variable, according to literature reports, yet 
typically much lower than the dose used for therapeutic purposes1,3. Hypotensive episodes were also reported in 
three recent studies in children and young adults in whom ferumoxytol was used as MR contrast agent16–18. In one 
of these studies, serum creatinine and urea concentrations were measured and found unaltered by ferumoxytol16. 
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Besides this single study, there are, to the best of our knowledge, no published reports on effects of ferumoxytol 
on the kidney. In particular, there are no data available with regard to its possible effects on renal hemodynamics 
and oxygenation. Such data are urgently needed, because, according to basic methodologic principles, it must be 
ascertained that a method intended to measure a certain variable does not per se alter this variable.
Realizing this lack of essential methodological data and recognizing the need of ferumoxytol-based monitor-
ing of the renal blood volume fraction for a comprehensive assessment of renal hemodynamics and oxygenation, 
this work examines whether the substance itself may affect regulation of renal hemodynamics and oxygenation. 
To meet this goal, in vivo measurements of arterial blood pressure (ABP), total renal blood flow (RBF), local 
perfusion (laser-Doppler-flux) and tissue partial pressure of oxygen (pO2) in the renal cortex and medulla were 
employed11,19–22. Modulation of renal hemodynamics and oxygenation was accomplished by dedicated test inter-
ventions, including brief periods of aortic occlusion, hypoxia and hyperoxia11,19–21. Three (cumulative) doses of 
ferumoxytol were studied including a low dose regime based upon previous studies that monitored the blood 
volume fraction of the brain and kidneys in rats6,7 and a high dose regime that corresponds with the human 
equivalent dose (based upon body surface area)23 for the therapeutic use of ferumoxytol.
Results
The surgical preparation and physiological experimentation to study regulation of renal hemodynamics and oxy-
genation was performed in 10 anesthetized rats, yet for anatomical and/or technical reasons, reliable data on 
RBF, cortical Laser-flux, and cortical pO2 could only be obtained in 9 rats, and data on medullary Laser-flux and 
medullary pO2 in 8 rats.
Prior to all interventions, the absolute baseline values for ABP, RBF, and tissue pO2 were recorded: ABP 
98.3 ± 5.8 mmHg, RBF 4.86 ± 0.83 ml/min, cortical tissue pO2 23.8 ± 3.2 mmHg, and medullary tissue pO2 
17.5 ± 3.0 mmHg. The laser-Doppler-flux-technique used to assess cortical and medullary perfusions allows to 
monitor relative changes yet does not provide absolute values21.
Figure 1 depicts the time course for all physiological parameters upon injection of saline (control) and upon 
injection of three cumulative doses of ferumoxytol. Apart from minor short-lasting fluctuations, the saline injec-
tion did not result in sustained changes in any of the physiological parameters under investigation. Likewise, none 
of the three injections of ferumoxytol resulted in marked sustained changes in any parameter, and there were no 
significant changes as compared to saline.
Figure 2 illustrates the time courses during suprarenal aortic occlusion and recovery. Under control con-
ditions, the inflation of the occluder resulted in an immediate drop in renal arterial pressure (RAP). Similarly, 
RBF approached zero instantaneously upon onset of the occlusion; the fall in cortical and medullary fluxes was 
less abrupt. Cortical and medullary pO2 started to decrease shortly thereafter and reached nadirs only upon the 
release of the occlusion, after 60 sec. In response to the deflation of the occluder, RAP rapidly increased to about 
80% of baseline followed by a gradual approach to baseline within 120 sec. RBF and the fluxes increased rapidly 
and approached baseline earlier than RAP. Cortical and medullary pO2 increased more slowly and reached their 
respective baseline values 150 and 120 sec after the release of the occlusion. None of the three doses of ferumoxy-
tol resulted in significant changes in any of the physiological parameters measured, as compared to saline.
Figure 3 surveys the time courses obtained in response to the hypoxic stimulus with an inspiratory fraction 
of oxygen (FiO2) of 10%. Under control conditions, ABP decreased continuously during the 60 sec of hypoxia, 
reaching about 70% of baseline. RBF decreased to a much lesser extent; cortical flux showed a small increase and 
medullary flux showed some fluctuations only. Cortical and medullary pO2 decreased continuously, reaching 
about 65% and 75% of their respective baseline values toward the end of the hypoxic period. With the restoration 
of normoxia (FiO2 21%), all parameters returned to their respective baseline values within the recovery period 
of 200 sec. Similarly to the aortic occlusion and recovery intervention, none of the three doses of ferumoxytol 
resulted in any significant changes in all measured physiological parameters, as compared to the saline reference.
Figure 4 shows the time courses obtained in response to hyperoxia (FiO2 100%). Under control conditions, 
ABP increased during the 180 sec of hyperoxia, reaching about 16% above baseline. Interestingly, ferumoxytol 
tended to blunt the hyperoxia-induced increase in ABP in a dose-dependent manner. At the highest dose, the 
pressure rise was significantly lower as compared to saline. On the other hand, none of the three doses of feru-
moxytol resulted in significant changes in any other physiological parameter as compared to saline. Under both 
control and ferumoxytol conditions, RBF and cortical flux showed a small insignificant decrease and medullary 
flux some fluctuations. Even in cortical and medullary pO2, which increased continuously (reaching values about 
2.2-fold and 1.5-fold their respective baseline values) over the hyperoxic time-frame, there were no significant 
changes during ferumoxytol treatment. With the restoration of normoxia (FiO2 21%), all parameters returned to 
their respective baseline values within the recovery period of 200 sec.
Discussion
This work adds to the literature by exploring the potential acute in vivo effects of ferumoxytol on renal hemody-
namics and oxygenation. Our main finding is that intravenously injected ferumoxytol has only a marginal impact 
on the regulation of renal hemodynamics and oxygenation in healthy rats. Interestingly, the only significant effect 
observed was a blunting of the hyperoxia-induced increase in arterial pressure at a cumulative dose of 41 mg Fe/kg, 
a high dose that corresponds with the human equivalent dose for iron supplementation. Our results clearly show 
no immediate risk of impaired renal oxygenation or perfusion inherent to an injection of ferumoxytol, thereby 
rendering ferumoxytol a favourable contrast medium suitable for the quantification and monitoring of changes 
in renal blood volume fraction.
Regulation of renal hemodynamics and oxygenation was studied with periods of aortic occlusion, hypoxia, 
and hyperoxia. The responses to these interventions are brought about by complex interactions of renal and extra-
renal mechanisms. Occlusion of the suprarenal aorta results in abrupt cessation of blood flow into the kidney. 
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As renal O2 consumption initially remains unaltered, renal tissue pO2 declines rapidly. This leads to intrarenal 
vasodilation, which is augmented by accumulation of CO2 as well as by the mechanisms of autoregulation of 
RBF20,24,25. Vasodilation also takes place in the extrarenal tissues downstream of the occluder. By deflating the 
occluder, the kidney and the extrarenal tissues are reperfused. Due to the initially sustained vasodilation, systemic 
arterial pressure drops25. This is detected by arterial baroreceptors and actuates the baroreflex response which 
results in renal and extrarenal vasoconstriction. Again, mechanisms of RBF autoregulation contribute to the com-
pensatory renal vasoconstriction25. That ferumoxytol did not alter the complex response to aortic occlusion and 
recovery (Fig. 2) indicates that all elements contributing to this response were left unaffected by the compound.
Likewise, ferumoxytol did not affect the mechanisms that govern the responses to hypoxia (Fig. 3). Switching 
the inspiratory oxygen fraction to 10% results in moderate arterial hypoxemia so that tissue pO2 in all vas-
cular beds gradually decreases. Of course, renal tissue hypoxia is by far milder than during aortic occlusion. 
The ensuing systemic and renal vasodilation triggers counteraction by the baroreflex and the mechanisms of 
Figure 1. No sustained changes in physiological readings following ferumoxytol injections. Relative 
changes in arterial pressure, renal blood flow (transonic probe), cortical and medullary tissue perfusion (Flux, 
laser-Doppler-flux probes), and cortical and medullary tissue oxygen tension (pO2, fluorescence-quenching 
probes) upon injection of isotonic saline (volume Control), and three consecutive injections of ferumoxytol to 
achieve cumulative doses of 6, 10, and 41 mg Fe/kg body mass (6 FO, 10 FO, 41 FO). Data are mean ± SEM.
www.nature.com/scientificreports/
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RBF autoregulation. In addition, the systemic hypoxemia is detected by arterial chemoreceptors that actuate a 
reflex response that increases ventilation. This results in lower rather than higher pCO2 which also counteracts 
vasodilation24–26.
Ferumoxytol did not significantly affect the responses to hyperoxia, with the exception of arterial pressure at 
the highest ferumoxytol dose (Fig. 4). The hyperoxia-induced pressure increase is due to vasoconstriction, prefer-
entially in extrarenal vascular beds27,28. It is presumed to largely rely on direct impact of hyperoxia on the micro-
vasculature, where increased pO2, probably via reactive oxygen species, can induce an imbalance of vasoactive 
factors including nitric oxide (NO), endothelin, and prostaglandins29,30. The mechanism(s) by which ferumoxytol 
blunted this response are completely unknown. One could hypothesize that ferumoxytol particles may increase 
the shear stress in the erythrocyte-free plasma cuff layer in the microvasculature, whereby it might counteract the 
hyperoxia-induced decrease in endothelial NO production. Taken together, our results indicate that the influence 
Figure 2. Ferumoxytol does not influence physiological changes during suprarenal aortic occlusion and 
recovery. Relative changes in renal arterial pressure, renal blood flow, cortical and medullary tissue perfusion 
(Flux), and cortical and medullary tissue oxygen tension (pO2) upon suprarenal aortic occlusion for 60 sec 
followed by restoration of the perfusion at cumulative ferumoxytol doses of 0 (Control), 6, 10, and 41 mg Fe/kg 
body mass (6 FO, 10 FO, 41 FO). Data are mean ± SEM.
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of ferumoxytol on regulation of renal hemodynamics and oxygenation in rats is negligible and make it an ideal 
candidate for MR-based assessment of the renal blood volume fraction.
Renal tissue hypoperfusion and hypoxia are considered to be key elements in the pathophysiology of acute 
kidney injury and its possible progression to CKD31–34. Because BOLD MRI offers a noninvasive technique to 
obtain insight into renal oxygenation, it is increasingly leveraged for the study of acute and chronic kidney dis-
eases and its swift translation into the clinical realm10–14. Yet, the blood volume fraction is a major confounder 
of the relationship between T2* and tissue pO2 10,11. For a number of reasons, the impact of the kidney’s blood 
volume fraction is greater than that of other organs. As compared per tissue weight, total renal blood flow is much 
higher than that of most other tissues, thus renal vasoconstrictive or vasodilatory effects elicited by neuronal, 
endocrine, paracrine, and metabolic factors as well as by the mechanisms of RBF autoregulation will probably 
result in larger changes10,21,32,35. In fact, substantial changes in the renal blood volume fraction were reported for 
a number of experimental settings7,11,20. Moreover, the tubules are a unique feature of the kidney. Their volume 
Figure 3. No changes in physiological parameters by ferumoxytol during hypoxic challenge. Relative 
changes in arterial blood pressure, renal blood flow, cortical and medullary tissue perfusion (Flux), and cortical 
and medullary tissue oxygen tension (pO2) upon a hypoxic challenge (inspiratory oxygen 10%) at cumulative 
ferumoxytol doses of 0 (Control), 6, 10, and 41 mg Fe/kg body mass (6 FO, 10 FO, 41 FO). Data at time 260 sec 
indicate that all variables had returned to baseline values at the end of the respective recovery period (200 sec of 
normoxia). Data are mean ± SEM.
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fraction is quite large and can rapidly change due to changes in glomerular filtration, alterations in tubular out-
flow towards the pelvis, changes in tubular fluid resorption, and modulation of the transmural pressure gradient. 
As the renal capsule is rather tough, changes in the tubular volume fraction will often result in circular distension 
or compression of intrarenal vessels, which will inevitably change the blood volume fraction10. The added com-
plexity may very well confound interpretation of BOLD-MRI obtained from patients who suffer from renal disor-
ders35–38. Thus, assessment of the renal blood volume fraction and its changes under various (patho-)physiological 
conditions is mandatory for an unambiguous interpretation of renal BOLD-MRI.
The use of ferumoxytol is conceptually appealing for the pursuit of MR-based assessment/monitoring of the 
renal blood volume fraction. Like other ultrasmall superparamagnetic iron oxide (USPIO) particles, ferumoxytol 
does not readily extravasate and is not filtered in the glomeruli, so it has a sufficiently long plasma half-life (about 
2 h in rats; about 15 h in humans)1,2,7. Unlike other USPIOs, ferumoxytol has the advantage that it is approved for 
Figure 4. Ferumoxytol blunts ABP increase during a hyperoxic challenge. Relative changes in arterial blood 
pressure, renal blood flow, cortical and medullary tissue perfusion (Flux), and cortical and medullary tissue 
oxygen tension (pO2) upon a hyperoxic challenge (inspiratory oxygen 100%) at cumulative ferumoxytol doses 
of 0 (Control), 6, 10, and 41 mg Fe/kg body mass (6 FO, 10 FO, 41 FO). Data at time 380 sec indicate that all 
variables had returned to baseline values at the end of the respective recovery period (200 sec of normoxia). 
Data are mean ± SEM; * denotes significant difference (ANOVA for repeated measurements followed by 
Bonferroni’s multiple comparison procedure).
www.nature.com/scientificreports/
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intravenous injection in humans–although it is, of course, off-label when used as contrast agent. The magnetite 
core of ferumoxytol is covered by a coating of polyglucose sorbitol carboxymethylether that hinders contact of 
the iron with blood plasma, thus allowing relatively fast administration. The commercially available solution 
(Feraheme) has an average particle size of 23 nm with a narrow particle size distribution6. The rather slow elim-
ination of ferumoxytol from the blood pool occurs via phagocytosis by macrophages of the reticuloendothelial 
system1–3,7.
Ferumoxytol’s feasibility to monitor pharmacologically induced acute changes in renal blood volume fraction 
in rats has already been shown7. Our present study can be conceived as having accomplished the next manda-
tory step, i.e., to ascertain that ferumoxytol does itself not unduly affect regulation of renal hemodynamics and 
oxygenation in healthy rats. Whether this also applies to animals with renal disorders remains to be tested. The 
further experimental stage would be to determine the impact of changes in the blood volume fraction on the 
relationship between renal T2* and tissue pO2 under various (patho-)physiological conditions. This would ideally 
be done by use of an integrated approach such as MR-PHYSIOL that allows simultaneous monitoring of invasive 
physiological parameters and MR parameters in combination with in vivo dedicated test interventions of renal 
hemodynamics and oxygenation11,21. Of course, the impact of shifts in the oxyHb dissociation curve and changes 
in hematocrit on the relation between renal tissue pO2 and renal BOLD also remains to be determined10.
Our study has a number of limitations. First, we studied the effects of ferumoxytol on regulation of renal 
hemodynamics and oxygenation in anesthetized healthy rats. We did not observe any decrease in arterial 
blood pressure. This is not in line with previous reports on clinical studies that enrolled patients suffering from 
CKD-related anemia who received therapeutic doses (hypotensive effects in < 2% of patients) as well as studies 
where patients were administered ferumoxytol off-label as MR contrast (incidence of hypotensive episodes 0.4 
to 12%)1,3,16–18. Reasons behind this difference may include species differences and pre-existing disorders in the 
patients enrolled. Second, our study focussed on kidney hemodynamics and oxygenation so that the results may 
not apply to other organs or vascular beds. Finally, we chose two dosages of ferumoxytol based upon previous 
MR-studies on the blood volume fraction of the brain and kidneys in rats6,7. In addition, we studied the effects of 
the very high dose (41 mg Fe/kg) that accords with the human equivalent dose for iron supplementation. Human 
equivalent doses that are based on body surface area are required by authorities for determining the drug safety 
profile23. Thus, our results indicate a rather broad safety margin when typical ferumoxytol doses for MR contrast 
are applied. We are quite confident that even lower doses than our lowest dose (6 mg Fe/kg of BM) will suffice to 
study the impact of renal blood volume fraction on BOLD-MRI in rats.
To conclude, this study demonstrates the absence of any adverse acute effects of ferumoxytol on the regulation 
of renal hemodynamics and oxygenation. This finding renders ferumoxytol a prime candidate for intravascu-
lar contrast agent-based assessment of renal blood volume fraction without confounding renal oxygenation or 
perfusion.
Materials and Methods
Animal Preparation. The study was approved by the Animal Welfare Administration of Berlin’s State Office 
of Health and Social Affairs in accordance with the German Animal Protection Law and the experiments were 
carried out in accordance with the approved guidelines. Experiments including all interventions were performed 
in ten male Wistar rats (250–350 g BM; Harlan-Winkelmann, Borchen, Germany). The animals received food and 
water ad libitum and were housed under standard conditions with environmental enrichment. For anesthesia, 
urethane (20% in distilled water; 6 ml/kg BM intraperitoneal; Sigma-Aldrich, Steinheim, Germany) was used 
throughout the surgical preparation and the examination. This approach provides anesthesia for several hours 
and leaves cardiovascular and respiratory reflexes largely undisturbed. The rats were positioned on a thermo-
stated table in order to maintain their body temperature at 37 °C.
A tracheal cannula was inserted to facilitate spontaneous breathing. Monitoring of absolute arterial blood 
pressure (in mmHg) that corresponds with renal arterial pressure (RAP) was achieved by placing a catheter into 
the femoral artery with its tip towards the aorta. The catheter was connected to a pressure transducer (DT-XX, 
Viggo-Spectramed, Swindon, UK) and amplifier (TAM-A Plugsys Transducer; Hugo Sachs Elektronik–Harvard 
Apparatus GmbH, March-Hugstetten, Germany). The femoral artery catheter also served for continuous saline 
infusion (1 ml/h) throughout the preparation and the experiment. Another catheter was inserted into the right 
jugular vein; this was used for subsequent injections of isotonic saline and ferumoxytol (see below).
The abdomen was opened by a midventral incision; during surgery and examination the abdominal cavity 
was filled with isotonic saline (37 °C). Monitoring of total renal blood flow was achieved by a flow probe 
(1RB, Transonic Systems, Ithaca, NY, USA) positioned around the left renal artery. This blood flow measurement 
relies on ultrasound transit time difference and thus provides absolute data (in ml/min). Monitoring of tissue 
pO2 and perfusion was enabled by two combined pO2/laser-Doppler-flux probes (pO2 E-Series Sensor; Oxford 
Optronics, Oxford, UK) that were inserted into the renal tissue, one into the medulla (about 4 mm from the 
renal capsule) the other one into the cortex (about 1.5 mm). The fluorescence-quenching optodes allow absolute 
measurements of tissue pO2 (in mmHg). The laser-Doppler-flux probes assess tissue perfusion by erythrocyte 
flux (arbitrary units), thus, only relative changes in perfusion are monitored. For induction of aortic occlusions 
a remotely operated inflatable cuff was positioned around the aorta above the renal arteries. All parameters were 
continuously monitored and, following analog-to-digital conversion, the data were stored online with a sampling 
rate of 50 Hz.
Experimental Protocol and in vivo Interventions. Subsequent to the preparation, the experiments were 
started by recording baseline data of all parameters for 300 sec. The experimental protocol comprised four consec-
utive intravenous injections (after isotonic saline that served as volume control, three injections of ferumoxytol 
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followed to achieve cumulative doses of 6, 10, and 41 mg Fe/kg BM, respectively) at intervals of about 23 min. 
During the intervals, the response of all variables to the injections was recorded, followed by the test procedures 
to characterize regulation of renal hemodynamics and oxygenation under the respective conditions.
The reason we choose the cumulative escalating dosage procedure was as follows: The study’s goal was to test 
the working hypothesis that ferumoxytol is not suitable as MR contrast agent for renal studies because it affects 
regulation of renal hemodynamics/oxygenation. Thus, ferumoxytol’s effects had to be compared with the volume 
control, while comparisons among the doses of ferumoxytol are needless. The goal to test the working hypothesis 
had to be achieved with as small a number of animals as possible, as stipulated by the German Animal Protection 
Law. The interval of about 23 min between injections was chosen to balance two competing constraints: on one 
hand, the interval should be as short as possible such that the plasma concentration of ferumoxytol remains 
nearly constant between injections (plasma half-live time of about 2 hours). On the other hand, the test proce-
dures (aortic occlusion, hypoxia, hyperoxia) consume time, not the least because we had to allow ample time for 
full recovery following each intervention.
Each injection was preceded by a recording of baseline data. The injections amounted to 1 ml/kg BM, and were 
slowly administered (about 45 sec) into the jugular vein. The small volume and the rather slow injection rate were 
chosen in order to prevent that some kind of adaptation to a “volume expansion” may occur. In order to adminis-
ter the same volume of saline and of each of the three doses of ferumoxytol, Feraheme (AMAG Pharmaceuticals, 
Inc., Waltham, MA, USA) was diluted with isotonic saline for the two lower doses and was used undiluted at 
the highest dose. The first dose of ferumoxytol contained 6 mg Fe/kg BM, the second dose contained 4 mg Fe/kg 
BM to achieve a cumulative dose of 10 mg Fe/kg BM, and the third dose contained 31 mg Fe/kg BM to achieve a 
cumulative dose of 41 mg Fe/kg BM. The response to the injection of saline and the three doses of ferumoxytol, 
respectively, was recorded for 300 sec post injection (results shown by Fig. 1).
In the ongoing intervals between the injections, the tests used to characterize regulation of renal hemodynam-
ics and oxygenation were then performed. This comprised suprarenal aortic occlusion, hypoxia, and hyperoxia, 
each preceded by recording of baseline data and followed by a recovery period. Aortic occlusion was initiated by 
inflating the suprarenal aortic occluder, lasted for 60 sec, and was followed by 200 sec of recovery (results shown 
by Fig. 2). Hypoxia was induced by decreasing FiO2 from 21% (room air) to 10% via changing the gas flow to 
the tracheal cannula to 10% O2/90% N2 for 60 sec (results shown by Fig. 3), then, FiO2 was restored to 21%, and 
200 sec allowed for recovery. FiO2 was monitored using a Capnomac AGM-103 (Datex GE, Chalfont St. Gils, UK). 
Hyperoxia was induced by increasing FiO2 from 21% to 100% via changing the gas flow to pure oxygen for 180 sec 
(results shown by Fig. 4), then, FiO2 was restored to 21%, and 200 sec allowed for recovery.
Statistical Analysis. Relative values were obtained by relating the absolute data after initiating a given inter-
vention to the absolute data obtained immediately before this intervention. All data are given as mean ± SEM. 
Statistical analyses were done by analysis of variance (ANOVA) for repeated measurements, followed by the 
Bonferroni’s multiple comparison procedure with a significance level of P < 0.05 using Number Cruncher 
Statistical Software (Hintze, Kaysville, UT, USA).
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